These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24535888)

  • 1. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies.
    Tarral A; Blesson S; Mordt OV; Torreele E; Sassella D; Bray MA; Hovsepian L; Evène E; Gualano V; Felices M; Strub-Wourgaft N
    Clin Pharmacokinet; 2014 Jun; 53(6):565-80. PubMed ID: 24535888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness.
    Torreele E; Bourdin Trunz B; Tweats D; Kaiser M; Brun R; Mazué G; Bray MA; Pécoul B
    PLoS Negl Trop Dis; 2010 Dec; 4(12):e923. PubMed ID: 21200426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness.
    Kaiser M; Bray MA; Cal M; Bourdin Trunz B; Torreele E; Brun R
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5602-8. PubMed ID: 21911566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2-3 trial.
    Kande Betu Kumesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Nganzobo Ngima P; Mahenzi Mbembo H; Fina Lubaki JP; Lumeya Vuvu S; Kuziena Mindele W; Ilunga Wa Kyhi M; Mandula Mokenge G; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Glob Health; 2022 Nov; 10(11):e1665-e1674. PubMed ID: 36179736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole.
    Watson JA; Strub-Wourgraft N; Tarral A; Ribeiro I; Tarning J; White NJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
    Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fexinidazole: First Global Approval.
    Deeks ED
    Drugs; 2019 Feb; 79(2):215-220. PubMed ID: 30635838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
    Wyllie S; Patterson S; Stojanovski L; Simeons FR; Norval S; Kime R; Read KD; Fairlamb AH
    Sci Transl Med; 2012 Feb; 4(119):119re1. PubMed ID: 22301556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study.
    Tarral A; Hovsepian L; Duvauchelle T; Donazzolo Y; Latreille M; Felices M; Gualano V; Delhomme S; Valverde Mordt O; Blesson S; Voiriot P; Strub-Wourgaft N
    Clin Pharmacokinet; 2023 Mar; 62(3):481-491. PubMed ID: 36763327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotoxicity profile of fexinidazole--a drug candidate in clinical development for human African trypanomiasis (sleeping sickness).
    Tweats D; Bourdin Trunz B; Torreele E
    Mutagenesis; 2012 Sep; 27(5):523-32. PubMed ID: 22539226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease.
    Bahia MT; Nascimento AF; Mazzeti AL; Marques LF; Gonçalves KR; Mota LW; Diniz Lde F; Caldas IS; Talvani A; Shackleford DM; Koltun M; Saunders J; White KL; Scandale I; Charman SA; Chatelain E
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4362-70. PubMed ID: 24841257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis.
    Burrell-Saward H; Harris AJ; de LaFlor R; Sallam H; Alavijeh MS; Ward TH; Croft SL
    Int J Antimicrob Agents; 2017 Aug; 50(2):203-209. PubMed ID: 28552771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics.
    Bramer SL; Forbes WP
    Clin Pharmacokinet; 1999; 37 Suppl 2():13-23. PubMed ID: 10702883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fexinidazole for the treatment of human African trypanosomiasis.
    Fairlamb AH
    Drugs Today (Barc); 2019 Nov; 55(11):705-712. PubMed ID: 31840685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436.
    Jennings FW; Atouguia JM; Murray M
    Trop Med Int Health; 1996 Oct; 1(5):590-8. PubMed ID: 8911443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A DBS method for quantitation of the new oral trypanocidal drug fexinidazole and its active metabolites.
    Filali-Ansary A; Augé C; Abgrall A; Souchaud M; Pellissier F; Mordt OV; Blesson S; Sanderink GJ
    Bioanalysis; 2016 Oct; 8(19):2045-63. PubMed ID: 27611920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
    Stampfuss J; Kubitza D; Becka M; Mueck W
    Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.